Ajanta Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+17.3%+13.4%
EBITDA+10.8%+21.2%
Net Income+14.7%+21.5%
EPS (adj.)+14.7%+21.5%
Total Assets+22.7%+9.6%
Total Equity+19.5%+10.1%
Free Cash Flow−80.5%−35.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AJANTPHARM₹3,459.80

Ajanta Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALKEMIPCALABTORNTPHARMABBOTINDIAANTHEMGLAXOMEDANTAGLENMARKMcap ₹43,369 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+17.3+13.4
EBITDA+10.8+21.2
Net Income+14.7+21.5
EPS (adj.)+14.7+21.5
Total Assets+22.7+9.6
Total Equity+19.5+10.1
Free Cash Flow-80.5-35.7
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.